Mitsubishi Tanabe Pharma Corporation

Fujitsu Corporation

Sanofi-Aventis

Sanofi

Mitsubishi Pharma Corporation

Kenji Fukunaga

Kazutoshi Watanabe

Toshiyuki Kohara

Fumiaki Uehara

Satoshi Yokoshima

Tamotsu Matsuo

Masahiro Okuyama

Shinsuke Hiki

Takumi Iwai

Atsuki Taniguchi

Kazuo Takatsu

Norimitsu Hayashi

Yoshihiro Usui

Daisuke Iijima

Toshihiro Koji

Hideki Horiuchi

Hiroshi Urano

Masayuki Ogawa

Pascal Barneoud

Kenji Usui

Jesus Benavides

Jeremy Pratt

Satoshi Fukui

Kazuki Nakayama

Tokushi Hanano

Aya Shoda

Keiichi Aritomo

Tatsuya Oku

Daiki Sakai

Hideki Shiono

Masatake Fujimura

Shuichi Nakagawa

Koji Komatsu

Satoshi Tomie

Takanori Yasui

Hirofumi Fujiyama

Nobuaki Fujimoto

Noriaki Itagaki

Shin-ichi Kusaka

Hirotaka Okabe

Shinichi Hara

Akihiro Takahashi

Masao Sugahara

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

Bicyclic heterocyclic compound

The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group,

Bicyclic or tricyclic heterocyclic compound

A demultiplexing device includes a first demultiplexer configured to demultiplex a first input signal, a second demultiplexer configured to demultiplex a second input signal, and a switching circuit configured to set an input destination of signals demultiplexed and output by each of the first demultiplexer and the second demultiplexer based on data rates of the first and second input signals. A multiplexing device includes a first multiplexer configured to multiplex a first input signal, a second multiplexer configured to multiplex a second input signal, and a switching circuit configured to set an input destination of signals multiplexed and output by the first multiplexer and the second multiplexer based on data rates of the first and second input signals.

Demultiplexing device and multiplexing device

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein each Rrepresents hydrogen atom or the like; X represents oxygen atom or the like; A represents a C-Ccycloalkyl group, a C-Caryl group or a heterocyclic group; Rrepresents a halogen atom or the like; s represents 0 or an integer of 1 to 5; Q represents a pyridine ring which may be substituted or pyrimidine ring; and Rrepresents hydrogen atom or the like, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease). 

2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein Rrepresents a hydrogen or the like; Rrepresents methyl group or the like; Rrepresents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; Rrepresents hydrogen or the like; Rrepresents hydrogen or the like; Rrepresents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH, oxygen atom, NH, or the like; any one or more of Rand R, Rand R, Rand R, X and R, X and R, X and R, and Rand Rmay combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

2-(cyclic amino)-pyrimidone derivatives

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

6-pyrimidinyl-pyrimid-4-one derivative

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein Rrepresents a C-Calkyl; Rrepresents a hydrogen atom or the like; Rrepresents a halogen or the like; q represents an integer of 1 to 7; Rrepresents a halogen or the like; p represents 0 or an integer of 1 to 5; Rrepresents a C-Caryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C-Calkyl; Rrepresents a hydrogen atom, or the like; R' represents a C-Calkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C-Calkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease). 

2-morpholino-4-pyrimidone compound

In a communication apparatus, a write controller writes received data in a temporary memory which serves as short-time storage. A read controller reads data out of the temporary memory. A discard controller controls discard operation of the data read out of the temporary memory.

Communication apparatus with data discard functions and control method therefor

A data communication apparatus has a data retainer, a retain state manager, a guaranteed bandwidth manager, a surplus bandwidth manager managing outputting of output data having a destination retained in the data retainer to an output line on a per-destination basis when the output data is outputted to the output line with the use of a surplus bandwidth that is a surplus over a sum of guaranteed bandwidths, and a scheduler scheduling outputting of data retained in the data retainer to the output line, based on results of managements by the guaranteed bandwidth manager and the surplus bandwidth manager and a retain state managed by the retain state manager. The apparatus manages the bandwidth with improved accuracy at the time of communication using a surplus bandwidth.

Data output apparatus, communication apparatus and switch apparatus

In a packet transmission method and device, when a received packet is written in a packet buffer, an address of the packet buffer is stored as a read address for each destination corresponding to a physical port and storing information of the received packet. The read address of a destination designated by the received packet information is read and saved when the received packet is read out of the packet buffer in accordance with a scheduling control. Then, the saved read address is taken out in accordance with an arbitration control and a received packet corresponding to the saved read address is read from the packet buffer.

Packet transmission method and device

A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C-Calkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C-Calkyl group, an optionally partially hydrogenated C-Caryl ring, an indan ring or the like; m represents an integer of 1 to 3; each independently represents a halogen atom, a hydroxy group, a cyano group, a C-Calkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C-Calkylene group. 

2,3,6-Trisubstituted-4-pyrimidone derivatives

The present invention is a technology concerning a reception pointer processing in an SDH transmission system. The objects of the invention are to identify automatically a frame size (frame composition) of the received transmission frame in the SDH (SONET) transmission system and to perform flexibly and rapidly a reception pointer processing corresponding to the frame size. These objects are realized by providing a reception pointer processing apparatus for performing the pointer processing of the transmission frame transmitted by the SDH transmission system, wherein the reception pointer processing apparatus comprises a pointer processing section for executing the required pointer processing of each unit frame contained in the transmission frame, and a frame composition identification section for identifying automatically the frame composition of the transmission frame based on the pointer processing result of the pointer processing section and for providing the identification result to the pointer processing section.

Reception pointer processing apparatus in SDH transmission system

Printed circuit boardstoare connected in a star-like configuration with a single packet processing IC, connected to a CPU, at its center, each printed circuit board being connected to the packet processing IC by a high-speed supervisory control linehaving a sufficient transmission capacity to transfer therethrough transparent information and alarm transfer information as well as information from the central processing unit in packet form, and the transparent information and the alarm transfer information are communicated between the printed circuit boards via the high-speed supervisory control line and via the packet processing IC, with provisions made for the packet processing IC to detect a destination from the packet information received from the originating printed circuit board and to transmit the packet information to the terminating printed circuit board. Further, provisions are made to transmit packetized cells to the terminating printed circuit board in accordance with time priority, thereby achieving a transmission line terminating apparatus with a reduced number of wiring lines.

Transmission line terminating apparatus that performs packet processing

Growing community of inventors

Osaka, Japan

Kenji Fukunaga